¼¼°èÀÇ Ç³¼± ´ëµ¿¸Æ ÆÇ¸· ¼ºÇü¼ú ½ÃÀå
Balloon Aortic Valvuloplasty
»óǰÄÚµå : 1758928
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 06¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 182 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,198,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,594,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

dz¼± ´ëµ¿¸Æ ÆÇ¸· ¼ºÇü¼ú ¼¼°è ½ÃÀåÀº 2030³â±îÁö 1¾ï 5,760¸¸ ´Þ·¯¿¡ À̸¦ Àü¸Á

2024³â¿¡ 1¾ï 2,780¸¸ ´Þ·¯·Î ÃßÁ¤µÇ´Â dz¼± ´ëµ¿¸Æ ÆÇ¸· ¼ºÇü¼ú ¼¼°è ½ÃÀåÀº 2030³â¿¡´Â 1¾ï 5,760¸¸ ´Þ·¯¿¡ À̸£°í, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 3.6%¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. º» º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ Non-Compliant BalloonsÀº CAGR 2.8%¸¦ ³ªÅ¸³»°í, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 1¾ï 10¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. Semi-Compliant Balloons ºÐ¾ß´Â ºÐ¼® ±â°£ Áß¿¡ CAGR 4.9%¼ºÀåÀÌ Àü¸ÁµË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 3,480¸¸ ´Þ·¯, Áß±¹Àº CAGR 6.5%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ Ç³¼± ´ëµ¿¸Æ ÆÇ¸· ¼ºÇü¼ú ½ÃÀåÀº 2024³â¿¡ 3,480¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 3,130¸¸ ´Þ·¯ ±Ô¸ð¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 6.5%·Î ÃßÁ¤µË´Ï´Ù. ±âŸ ÁÖ¸ñÇØ¾ß ÇÒ Áö¿ªº° ½ÃÀåÀ¸·Î¼­´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£Áß CAGRÀº °¢°¢ 1.5%¿Í 2.7%¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 2.0%¸¦ º¸ÀÏ Àü¸ÁÀÔ´Ï´Ù.

¼¼°èÀÇ Ç³¼± ´ëµ¿¸Æ ÆÇ¸· ¼ºÇü¼ú ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

¼øÈ¯±â ºÐ¾ß¿¡¼­ dz¼± ´ëµ¿¸Æ ÆÇ¸· ¼ºÇü¼ú¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁø ÀÌÀ¯´Â?

dz¼± ´ëµ¿¸Æ ÆÇ¸· ¼ºÇü¼ú(BAV)Àº ÀÓ»óÀû ¿ä±¸ÀÇ ÁøÈ­¿Í ÀûÀÀÁõ È®´ë·Î ÀÎÇØ Àü ¼¼°èÀûÀ¸·Î °ü½ÉÀÌ Å©°Ô ȸº¹µÇ°í ÀÖ½À´Ï´Ù. ÀüÅëÀûÀ¸·Î BAV´Â ¼ö¼úÀ̳ª °æÇÇÀû ´ëµ¿¸ÆÆÇ¸· ġȯ¼ú(TAVR)ÀÌ ºÎÀûÇÕÇÑ È¯ÀÚ¸¦ À§ÇÑ ¿ÏÈ­ Ä¡·á·Î ¿©°ÜÁ³À¸³ª, ÃÖ±Ù¿¡´Â TAVR Àü ÃÖÀûÈ­, ÆÇ¸· Æò°¡, °íÀ§Çè ȯÀÚ¸¦ À§ÇÑ ±³·® Ä¡·áÀÇ Àü·«Àû µµ±¸·Î ºÎ»óÇϰí ÀÖ½À´Ï´Ù. Àü ¼¼°èÀûÀ¸·Î ´ëµ¿¸ÆÆÇ¸·ÇùÂøÁõ¿¡ ´ëÇÑ ºÎ´ãÀÌ Áõ°¡Çϰí, ƯÈ÷ ¼±Áø±¹°ú ½ÅÈï±¹ ¸ðµÎ °í·ÉÈ­°¡ ÁøÇàµÊ¿¡ µû¶ó ½Ã¼ú À§ÇèÀº ³·Ãß°í Áõ»óÀº ¿ÏÈ­ÇÏ´Â Àúħ½ÀÀû Ä¡·á¹ý¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖÀ¸¸ç, BAV ±â¼úÀÌ ¹ßÀüÇÔ¿¡ µû¶ó ¿µ»ó À¯µµ, Ä«Å×ÅÍ µðÀÚÀÎ, ¼ö¼ú ÀüÈÄ ¸ð´ÏÅ͸µÀÇ °³¼±ÀÌ ÀÌ·ç¾îÁö°í ÀÖ½À´Ï´Ù. ¼ö¼úÀÇ ¾ÈÀü¼ºÀÌ Å©°Ô Çâ»óµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÇÏÀ̺긮µå ½ÉÀå ¼ö¼ú¿¡ BAV°¡ ÅëÇյǸ鼭 ±× ÀÓ»óÀû À¯¿ë¼ºÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù. ÀÇ·á ÀÚ¿øÀÌ Á¦ÇÑµÈ ±¹°¡¿¡¼­´Â BAV°¡ ÃÖÁ¾ ÆÇ¸· ġȯ¼úÀ» ±â´Ù¸®´Â ȯÀÚµéÀÇ Áõ»ó ¿ÏÈ­¸¦ À§ÇÑ ÀÓ½Ã ÇØ°áÃ¥À¸·Î ¿©ÀüÈ÷ ½ÇÇà °¡´ÉÇÑ ´ë¾ÈÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù. ¾ãÀº dz¼± Ä«Å×ÅÍ¿Í Á¤±³ÇÑ Ç÷¿ªÇÐ ¸ð´ÏÅ͸µÀÇ Çõ½ÅÀº ´õ ³ôÀº ¼º°ø·ü°ú ÇÕº´Áõ °¨¼Ò¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. µû¶ó¼­ BAV¸¦ µÑ·¯½Ñ ÀÓ»óÀû ÀνÄÀº BAV¸¦ ÃÖÈÄÀÇ º¸·ç·Î °£ÁÖÇÏ´Â °Í¿¡¼­ Á¾ÇÕÀûÀÎ ´ëµ¿¸ÆÆÇ¸·ÇùÂøÁõ °ü¸®ÀÇ Áß¿äÇÑ ¿ä¼Ò·Î ÀνÄÇÏ´Â °ÍÀ¸·Î º¯È­Çϰí ÀÖ½À´Ï´Ù.

ä¿ë·ü°ú ½Ã¼ú·®¿¡ Áö¿ª °ÝÂ÷°¡ ÀÖ´Â ÀÌÀ¯´Â ¹«¾ùÀΰ¡?

dz¼± ´ëµ¿¸ÆÆÇ¸· ¼ºÇü¼úÀÇ Àü ¼¼°è º¸±Þ·üÀº Áö¿ªº°·Î »ó´çÇÑ Â÷À̰¡ ÀÖÀ¸¸ç, ÀÌ´Â ÀÇ·á ÀÎÇÁ¶ó, °í±Þ ½ÉÇ÷°ü ½Ã¼³ÀÇ °¡¿ë¼º, °³¾÷ÀÇ ÈÆ·ÃÀÇ °ÝÂ÷¿¡ ¿µÇâÀ» ¹Þ½À´Ï´Ù. ¹Ì±¹, µ¶ÀÏ, ÀϺ»°ú °°Àº °í¼Òµæ ±¹°¡¿¡¼­´Â BAV°¡ ÀÀ±Þ ÁßÀç½Ã¼ú»Ó¸¸ ¾Æ´Ï¶ó TAVR ¹× ¼ö¼ú Àü °èȹ¿¡µµ Àû¿ëµÇ°í ÀÖ½À´Ï´Ù. À̵é Áö¿ªÀÇ ÁßÀçÀû ½ÉÀåÇÐ ¼¾ÅͰ¡ Àß ¹ß´ÞµÇ¾î ÀÖ°í, ÀÇ·áºñ º¸»ó Á¤Ã¥µµ Áö¿øÇϸç, °íÇØ»óµµ Åõ½Ã ¿µ»ó°ú ½ÉÃÊÀ½ÆÄ ¿µ»ó¿¡ ´ëÇÑ Á¢±Ù¼ºÀÌ ³ô¾ÆÁ® BAVÀÇ ½ÇÇà °¡´É¼º°ú ¾ÈÀü¼ºÀÌ Çâ»óµÇ°í ÀÖ½À´Ï´Ù. ¹Ý´ë·Î ¶óƾ¾Æ¸Þ¸®Ä«, ¾ÆÇÁ¸®Ä«, µ¿³²¾Æ½Ã¾ÆÀÇ ÀϺΠÁßÀú¼Òµæ ±¹°¡¿¡¼­´Â ¼÷·ÃµÈ ¼øÈ¯±â Àü¹®ÀÇ¿¡ ´ëÇÑ Á¢±ÙÀÌ Á¦ÇÑÀûÀ̰í, ½Ã¼ú ºñ¿ëÀÌ ºñ½Î°í, ÀÇ·Ú ÀÇ»çÀÇ ÀÎ½Ä ºÎÁ·À¸·Î ÀÎÇØ BAV°¡ ¾ÆÁ÷ ÃæºÐÈ÷ Ȱ¿ëµÇÁö ¸øÇϰí ÀÖ½À´Ï´Ù. ±×·¯³ª ¿ø°Ý ÀÇ·á¿Í À̵¿½Ä Ä«Å×ÅÍ·¦ÀÇ »õ·Î¿î ³ë·ÂÀ¸·Î ÀÎÇØ ¼­ºñ½º°¡ ÃæºÐÇÏÁö ¾ÊÀº Áö¿ª¿¡¼­ÀÇ Á¢±Ù¼ºÀÌ Á¡Â÷ °³¼±µÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ±¹Á¦ÀûÀÎ ÆÄÆ®³Ê½Ê°ú ÀÚ¼± »ç¾÷ ÅõÀÚ·Î ±³À° ¹× ±â¼ú ÀÌÀüÀÌ ÃËÁøµÇ°í ÀÖÀ¸¸ç, ½Ã¼úÀÇ Ç¥ÁØÈ­°¡ ÁøÇàµÇ°í ÀÖ½À´Ï´Ù. ¼øÈ¯±âÇÐȸÀÇ ÀÓ»ó °¡À̵å¶óÀεµ Àü ¼¼°è Áø·áÀÇ Á¶È­¿¡ ÀÏÁ¶Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Áö¿ªÀû Â÷ÀÌ´Â BAV¿Í °°Àº »ý¸íÀ» »ì¸®´Â ½ÉÀå ÁßÀç½Ã¼úÀ» ¸ðµç °æÁ¦Àû ȯ°æ¿¡¼­ °øÆòÇÏ°Ô ¹ÞÀ» ¼ö ÀÖµµ·Ï ÁßÀç½Ã¼ú ±³À°¿¡ ´ëÇÑ ÅõÀÚ, ±¹°æÀ» ÃÊ¿ùÇÑ Çù·Â, Á¤Ã¥Àû Áö¿øÀÌ Àý½ÇÇÏ´Ù´Â Á¡À» °­Á¶Çϰí ÀÖ½À´Ï´Ù.

Çõ½ÅÀº dz¼± ´ëµ¿¸Æ ÆÇ¸· ¼ºÇü¼úÀÇ ¹Ì·¡¸¦ ¾î¶»°Ô Çü¼ºÇϰí Àִ°¡?

±â±â ¼³°è, ¿µ»ó Áø´Ü ¹æ¹ý ¹× ½Ã¼ú ¿öÅ©Ç÷οìÀÇ Çõ½ÅÀûÀÎ ¹ßÀüÀ¸·Î dz¼± ´ëµ¿¸Æ ÆÇ¸· ¼ºÇü¼úÀÇ È¯°æÀÌ ºü¸£°Ô º¯È­Çϰí ÀÖ½À´Ï´Ù. »õ·Î¿î ¼¼´ëÀÇ Ç³¼± Ä«Å×ÅÍ´Â ³·Àº ÇÁ·ÎÆÄÀÏ, Çâ»óµÈ ÃßÀû¼º, ¿ø·¡ÀÇ ÆÇ¸· ±¸Á¶¿¡ ´ëÇÑ ¿ì¼öÇÑ ÀûÇÕ¼ºÀ» Ư¡À¸·Î Çϸç, À̸¦ ÅëÇØ ½Ã¼ú·Î ÀÎÇÑ ¿Ü»óÀ» ÁÙÀÌ°í ¿¹Ãø °¡´ÉÇÑ Ä¡·á °á°ú¸¦ ½±°Ô ¾òÀ» ¼ö ÀÖ½À´Ï´Ù. ½Ç½Ã°£ 3D ½ÉÃÊÀ½ÆÄ ¹× ½Ã¼ú Áß CT À¶ÇÕ ¿µ»ó°úÀÇ ÅëÇÕÀ» ÅëÇØ Á¤È®ÇÑ ÆÇ¸· À§Ä¡ °áÁ¤°ú ÆÇ¸·ÀÇ À̵¿¼º ¹× Ç÷¿ªÇп¡ ´ëÇÑ ½Ç½Ã°£ Æò°¡°¡ °¡´ÉÇÕ´Ï´Ù. ¿ä°ñµ¿¸Æ Á¢±ÙÀ» Æ÷ÇÔÇÑ ¸¶Ãë ÇÁ·ÎÅäÄݰú Ç÷°ü Á¢±Ù ±â¼úÀÇ Çõ½Å ¶ÇÇÑ ¼ö¼ú ÀüÈÄÀÇ À§ÇèÀ» ÃÖ¼ÒÈ­Çϰí ÀÔ¿ø ±â°£À» ´ÜÃàÇϰí ÀÖ½À´Ï´Ù. ÀϺΠÀåºñ Á¦Á¶¾÷üµéÀº ¼ö¼ú ÇÕº´ÁõÀ» ´õ¿í ÁÙÀ̱â À§ÇØ »ýºÐÇØ¼º dz¼± ±â¼úÀ» ¿¬±¸Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÆÇ¸· ¼ºÇü¼ú°ú ¾à¹° Àü´Þ ¸ÞÄ¿´ÏÁò ¹× ½Ç½Ã°£ ¾Ð·Â ¸ð´ÏÅ͸µ¿ë ¼¾¼­¸¦ ÅëÇÕÇÑ º¹ÇÕ ÀåÄ¡ÀÇ °³¹ßÀº Ä¡·áÀû À¯¿ë¼ºÀÇ ÇѰ踦 ¶Ù¾î³ÑÀ» ż¼¸¦ °®Ãß°í ÀÖ½À´Ï´Ù. ƯÈ÷ À¯·´°ú ¹Ì±¹¿¡¼­´Â ȹ±âÀûÀÎ ½ÉÇ÷°ü°è ±â¼ú¿¡ ´ëÇÑ ÆÐ½ºÆ®Æ®·¢ ÁöÁ¤À¸·Î ÀÌ·¯ÇÑ »õ·Î¿î ±â±â¿¡ ´ëÇÑ ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎÀÌ °¡¼ÓÈ­µÇ°í ÀÖ½À´Ï´Ù. ÇÑÆí, AI ±â¹Ý ÇØºÎÇÐ ½Ã¹Ä·¹À̼ǰú ȯÀÚº° 3D ÇÁ¸°ÆÃ ¸ðµ¨À» ÀÌ¿ëÇÑ ½Ã¼ú °èȹÀÇ µðÁöÅÐÈ­´Â ½ÉÀå Àü¹®Àǰ¡ ´õ ³ôÀº Á¤È®µµ·Î °á°ú¸¦ ¿¹ÃøÇÒ ¼ö ÀÖ°Ô ÇÔÀ¸·Î½á ½Ã¼úÀÇ ½Å·Ú¼ºÀ» Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù. °á°úÀûÀ¸·Î ÀÌ·¯ÇÑ ±â¼ú Çõ½ÅÀº ´Ù¾çÇÑ È¯ÀÚ±º¿¡ ´ëÇÑ BAVÀÇ Àû¿ëÀ» È®´ëÇÒ »Ó¸¸ ¾Æ´Ï¶ó Á¤¹Ð ½ÉÀåÇÐ(Precision Cardiology)¿¡ÀÇ ÅëÇÕÀ» À§ÇÑ Åä´ë¸¦ ¸¶·ÃÇϰí ÀÖ½À´Ï´Ù.

¼¼°è ½ÃÀå È®´ë¸¦ ÃËÁøÇÏ´Â ÁÖ¿ä Ã˸ÅÁ¦´Â ¹«¾ùÀΰ¡?

dz¼± ´ëµ¿¸Æ ÆÇ¸· ¼ºÇü¼ú ½ÃÀåÀÇ ¼ºÀåÀº ÀÓ»ó ¼ö¿ä, ±â¼ú ¹ßÀü, ÀÇ·á ¼­ºñ½º Á¦°ø µ¿Çâ µî ¿©·¯ ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ÁÖ¿ä ¿øµ¿·ÂÀº Àü ¼¼°èÀûÀ¸·Î ´ëµ¿¸ÆÆÇ¸· ÇùÂøÁõÀÇ À¯º´·ü Áõ°¡, ƯÈ÷ °í·ÉÈ­·Î ÀÎÇØ Áï°¢ÀûÀÎ ÆÇ¸· ġȯ¼ú¿¡ ÀûÇÕÇÏÁö ¾ÊÀº °íÀ§Ç豺 ȯÀÚÀÇ ¼ö°¡ Áõ°¡Çϰí ÀÖ´Ù´Â Á¡ÀÔ´Ï´Ù. ÀÌ¿Í ÇÔ²² TAVRÀÇ Ã¤ÅÃÀÌ Áõ°¡ÇÔ¿¡ µû¶ó BAV°¡ Áغñ ¹× Æò°¡ µµ±¸·Î ´õ ¸¹ÀÌ »ç¿ëµÇ°í ÀÖÀ¸¸ç, ½Ã¼ú °Ç¼ö´Â ´õ¿í È®´ëµÇ°í ÀÖ½À´Ï´Ù. ±â¼úÀûÀ¸·Î´Â ´Ù¾çÇÑ ÇØºÎÇÐÀû, ÀÓ»óÀû ¿ä±¸¿¡ ¸Â´Â °í¼º´É dz¼± Ä«Å×ÅͰ¡ Ãâ½ÃµÇ¾î º¸´Ù ¾ÈÀüÇϰí È¿°úÀûÀÎ Ä¡·á°¡ °¡´ÉÇØÁ³½À´Ï´Ù. ÇÏÀ̺긮µå ½ÉÀå ½Ã¼ú Áõ°¡¿Í ¼ö¼ú ÀüÈÄ À§Çè °¨¼Ò¿¡ ÀÖ¾î BAVÀÇ ¿ªÇÒÀÌ ÁøÈ­Çϸ鼭 ÀÓ»óÀû ÀûÀÀÁõµµ È®´ëµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Àç¿øÀϼö ´ÜÃà°ú ÃÖ¼Òħ½ÀÀû ½Ã¼úÀ» Áß½ÃÇÏ´Â ÀÇ·á ÆÐ·¯´ÙÀÓÀÇ º¯È­·Î ÀÎÇØ ÀÇ·áÁøµéÀº BAV¿Í °°Àº ºñħ½ÀÀû ½Ã¼ú·Î ´«À» µ¹¸®°í ÀÖ½À´Ï´Ù. ¼ÒºñÀÚ ÇൿÀÇ °üÁ¡¿¡¼­ º¼ ¶§, ƯÈ÷ ¼ö¼ú ´ë±â ½Ã°£ÀÌ ±ä ½ÃÀå¿¡¼­ ȯÀÚµéÀÇ ÀνÄÀÌ ³ô¾ÆÁö¸é¼­ ÀúÀ§Çè, ÀϽÃÀûÀÎ ÇØ°áÃ¥¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ´Â °ÍÀÌ Ã¤Åÿ¡ ´õ¿í ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. ÁßÀçÀû ±â´ÉÀ» °®Ãá ¿Ü·¡ ½ÉÀå Ä¡·á ¼¾ÅÍÀÇ ÃâÇöµµ BAV¸¦ ´õ¿í Ä£¼÷ÇÏ°Ô ¸¸µé°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ºÏ¹Ì¿Í À¯·´ µî ÁÖ¿ä Áö¿ªÀÇ À¯¸®ÇÑ »óȯ Á¦µµ ÇÁ·¹ÀÓ¿öÅ©´Â ÀÀ±Þ ¹× ´ë±â ȯ°æ¿¡¼­ BAVÀÇ »ç¿ëÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¸¶Áö¸·À¸·Î, ƯÁ¤ °íÀ§Ç豺 ȯÀÚ±º¿¡¼­ BAVÀÇ È¿°ú¸¦ µÞ¹ÞħÇÏ´Â ¿¬±¸¿Í µ¥ÀÌÅͰ¡ Áõ°¡ÇÔ¿¡ µû¶ó BAV°¡ º¸´Ù ±¤¹üÀ§ÇÑ °¡À̵å¶óÀο¡ Æ÷ÇԵǰí, Çö´ë ½ÉÀå Ä¡·á Àü·«¿¡¼­ BAVÀÇ ÀÔÁö°¡ °­È­µÇ°í ÀÖ½À´Ï´Ù.

ºÎ¹®

Á¦Ç° À¯Çü(Non-Compliant Balloons, Semi-Compliant Balloons)

Á¶»ç ´ë»ó ±â¾÷ ¿¹(ÃÑ 44°³»ç)

AI ÅëÇÕ

´ç»ç´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AIÅø¿¡ ÀÇÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â LLM³ª ¾÷°è °íÀ¯ SLM¸¦ Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹ü¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÍ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº °¨¼Ò, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû ¹× °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Balloon Aortic Valvuloplasty Market to Reach US$157.6 Million by 2030

The global market for Balloon Aortic Valvuloplasty estimated at US$127.8 Million in the year 2024, is expected to reach US$157.6 Million by 2030, growing at a CAGR of 3.6% over the analysis period 2024-2030. Non-Compliant Balloons, one of the segments analyzed in the report, is expected to record a 2.8% CAGR and reach US$100.1 Million by the end of the analysis period. Growth in the Semi-Compliant Balloons segment is estimated at 4.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$34.8 Million While China is Forecast to Grow at 6.5% CAGR

The Balloon Aortic Valvuloplasty market in the U.S. is estimated at US$34.8 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$31.3 Million by the year 2030 trailing a CAGR of 6.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.5% and 2.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.0% CAGR.

Global Balloon Aortic Valvuloplasty Market - Key Trends & Drivers Summarized

What Is Driving Renewed Interest in Balloon Aortic Valvuloplasty in the Cardiovascular Space?

Balloon Aortic Valvuloplasty (BAV) is experiencing a significant resurgence in global interest, primarily driven by evolving clinical needs and expanding indications for use. Traditionally viewed as a palliative intervention for patients ineligible for surgical or transcatheter aortic valve replacement (TAVR), BAV has recently emerged as a strategic tool in pre-TAVR optimization, valve assessment, and as a bridging therapy for high-risk patients. The growing global burden of aortic stenosis, particularly among aging populations in both developed and emerging economies, underscores the demand for minimally invasive interventions that offer symptomatic relief with a lower procedural risk. As BAV techniques improve, procedural safety has seen marked advancement due to better imaging guidance, catheter designs, and perioperative monitoring. Furthermore, the integration of BAV in hybrid cardiac procedures has widened its clinical utility. In nations where healthcare resources are limited, BAV remains a viable interim solution for symptom relief in patients awaiting definitive valve replacement. Technological innovation in low-profile balloon catheters and refined hemodynamic monitoring has contributed to higher success rates and reduced complications. As such, clinical perceptions surrounding BAV are shifting from viewing it as a last-resort option to recognizing it as a critical component of comprehensive aortic stenosis management, particularly in fragile patients who are unable to undergo definitive procedures immediately.

Why Is There a Regional Disparity in Adoption Rates and Procedural Volumes?

The global adoption of Balloon Aortic Valvuloplasty varies considerably across regions, influenced by disparities in healthcare infrastructure, availability of advanced cardiovascular facilities, and practitioner training. In high-income countries such as the United States, Germany, and Japan, BAV is increasingly employed not only in emergency interventions but also in preoperative planning for TAVR and surgical procedures. The sophistication of interventional cardiology centers in these regions, alongside supportive reimbursement policies and widespread access to high-resolution fluoroscopy and echocardiographic imaging, enhances the feasibility and safety of BAV. Conversely, in lower-middle-income countries across Latin America, Africa, and parts of Southeast Asia, BAV remains underutilized due to limited access to trained cardiologists, high procedural costs, and lack of awareness among referring physicians. However, emerging initiatives in telemedicine and mobile cath labs are slowly improving access in underserved areas. Moreover, international partnerships and philanthropic investments are facilitating training and technology transfers, allowing for greater procedural standardization. Clinical guidelines from cardiology societies are also playing a role in harmonizing practices globally. This regional variation highlights a pressing need for investment in interventional training, cross-border collaborations, and policy support to ensure equitable access to life-saving cardiac interventions like BAV across all economic settings.

How Is Innovation Shaping the Future of Balloon Aortic Valvuloplasty?

Innovative strides in device design, imaging modalities, and procedural workflows are rapidly transforming the landscape of Balloon Aortic Valvuloplasty. New-generation balloon catheters are characterized by lower profiles, enhanced trackability, and superior conformability to the native valve anatomy, which together reduce procedural trauma and facilitate more predictable outcomes. Integration with real-time 3D echocardiography and intraprocedural CT fusion imaging allows for precise valve positioning and real-time assessment of leaflet mobility and hemodynamic response. Innovations in anesthesia protocols and vascular access techniques, including the use of radial artery access, are also minimizing perioperative risks and reducing hospital stay durations. Some device manufacturers are even exploring biodegradable balloon technologies to further reduce procedural complications. Moreover, the development of combination devices that integrate valvuloplasty with drug delivery mechanisms or sensors for real-time pressure monitoring is poised to push the boundaries of therapeutic utility. Regulatory approvals for such novel devices are accelerating, particularly in Europe and the U.S., driven by fast-track designations for breakthrough cardiovascular technologies. Meanwhile, the digitization of procedural planning using AI-based anatomical simulations and patient-specific 3D-printed models is allowing cardiologists to anticipate outcomes with greater accuracy, improving procedural confidence. As a result, these innovations are not only expanding the applicability of BAV across diverse patient segments but are also laying the groundwork for its integration into precision cardiology.

What Are the Key Catalysts Fueling Market Expansion Globally?

The growth in the Balloon Aortic Valvuloplasty market is driven by several factors rooted in clinical demand, technological advancements, and healthcare delivery trends. A primary driver is the rising prevalence of aortic stenosis globally, especially among the aging population, which has increased the number of high-risk patients unsuitable for immediate valve replacement. In parallel, the growing adoption of TAVR has led to greater use of BAV as a preparatory and evaluative tool, further expanding procedural volumes. Technologically, the availability of high-performance balloon catheters that cater to different anatomical and clinical needs has made the intervention safer and more effective. The increase in hybrid cardiac procedures and the evolving role of BAV in perioperative risk mitigation have also expanded its clinical indications. Additionally, shifting healthcare paradigms that emphasize shorter hospital stays and minimally invasive procedures are pushing providers toward less intensive interventions like BAV. From a consumer behavior standpoint, greater patient awareness and demand for low-risk, temporary solutions, especially in markets with long surgical wait times, are further influencing adoption. The emergence of outpatient cardiac care centers equipped with interventional capabilities is also making BAV more accessible. Moreover, favorable reimbursement frameworks in key regions such as North America and Europe are encouraging its use in both emergency and elective settings. Finally, increasing research and data supporting the efficacy of BAV in specific high-risk cohorts are prompting broader guideline inclusion, thus reinforcing its place in modern cardiac care strategies.

SCOPE OF STUDY:

The report analyzes the Balloon Aortic Valvuloplasty market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Non-Compliant Balloons, Semi-Compliant Balloons)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â